|
1
|
Lu S, Yu Y, Chen Z, Ye X, Li Z and Niu X:
Maintenance therapy improves survival outcomes in patients with
advanced non-small cell lung cancer: A meta-analysis of 14 studies.
Lung. 193:805–814. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Casadio C, Guarize J, Donghi S, Di Tonno
C, Fumagalli C, Vacirca D, Dell'Orto P, De Marinis F, Spaggiari L,
Viale G, et al: Molecular testing for targeted therapy in advanced
non-small cell lung cancer: Suitability of endobronchial ultrasound
trans-bronchial needle aspiration. Am J Clin Pathol. 144:629–634.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Zarogoulidis P, Domvri K, Huang H and
Zarogoulidis K: Gene therapy for lung cancer malignant pleural
effusion: Current and future nano-biotechnology. Transl Lung Cancer
Res. 1:234–237. 2012.PubMed/NCBI
|
|
4
|
Cavazzana-Calvo M, Thrasher A and Mavilio
F: The future of gene therapy. Nature. 427:779–781. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Sharma A, Tandon M, Bangari DS and Mittal
SK: Adenoviral vector-based strategies for cancer therapy. Curr
Drug Ther. 4:117–138. 2009. View Article : Google Scholar :
|
|
6
|
Toloza EM, Morse MA and Lyerly HK: Gene
therapy for lung cancer. J Cell Biochem. 99:1–22. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Nemunaitis J, Swisher SG, Timmons T,
Connors D, Mack M, Doerksen L, Weill D, Wait J, Lawrence DD, Kemp
BL, et al: Adenovirus-mediated p53 gene transfer in sequence with
cisplatin to tumors of patients with non-small-cell lung cancer. J
Clin Oncol. 18:609–622. 2000.PubMed/NCBI
|
|
8
|
Schuler M, Herrmann R, De Greve JL,
Stewart AK, Gatzemeier U, Stewart DJ, Laufman L, Gralla R, Kuball
J, Buhl R, et al: Adenovirus-mediated wild-type p53 gene transfer
in patients receiving chemotherapy for advanced non-small-cell lung
cancer: Results of a multicenter phase II study. J Clin Oncol.
19:1750–1758. 2001.PubMed/NCBI
|
|
9
|
Schreiber J, Langhorst H, Jüttner R and
Rathjen FG: The IgCAMs CAR, BT-IgSF, and CLMP: Structure, function,
and diseases. Adv Neurobiol. 8:21–45. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Kim M, Zinn KR, Barnett BG, Sumerel LA,
Krasnykh V, Curiel DT and Douglas JT: The therapeutic efficacy of
adeno-viral vectors for cancer gene therapy is limited by a low
level of primary adenovirus receptors on tumour cells. Eur J
Cancer. 38:1917–1926. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Ma J, Zhao J, Lu J, Jiang Y, Yang H, Li P,
Zhao M, Liu K and Dong Z: Coxsackievirus and adenovirus receptor
promotes antitumor activity of oncolytic adenovirus H101 in
esophageal cancer. Int J Mol Med. 30:1403–1409. 2012.PubMed/NCBI
|
|
12
|
Li Y, Pong RC, Bergelson JM, Hall MC,
Sagalowsky AI, Tseng CP, Wang Z and Hsieh JT: Loss of adenoviral
receptor expression in human bladder cancer cells: A potential
impact on the efficacy of gene therapy. Cancer Res. 59:325–330.
1999.PubMed/NCBI
|
|
13
|
Pearson AS, Koch PE, Atkinson N, Xiong M,
Finberg RW, Roth JA and Fang B: Factors limiting
adenovirus-mediated gene transfer into human lung and pancreatic
cancer cell lines. Clin Cancer Res. 5:4208–4213. 1999.
|
|
14
|
Qin M, Chen S, Yu T, Escuadro B, Sharma S
and Batra RK: Coxsackievirus adenovirus receptor expression
predicts the efficiency of adenoviral gene transfer into non-small
cell lung cancer xenografts. Clin Cancer Res. 9:4992–4999.
2003.PubMed/NCBI
|
|
15
|
Hemminki A, Kanerva A, Liu B, Wang M,
Alvarez RD, Siegal GP and Curiel DT: Modulation of
coxsackie-adenovirus receptor expression for increased adenoviral
transgene expression. Cancer Res. 63:847–853. 2003.PubMed/NCBI
|
|
16
|
Zhang NH, Song LB, Wu XJ, Li RP, Zeng MS,
Zhu XF, Wan DS, Liu Q, Zeng YX and Zhang XS: Proteasome inhibitor
MG-132 modifies coxsackie and adenovirus receptor expression in
colon cancer cell line lovo. Cell Cycle. 7:925–933. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Lee CH, Kasala D, Na Y, Lee MS, Kim SW,
Jeong JH and Yun CO: Enhanced therapeutic efficacy of an
adenovirus-PEI-bile-acid complex in tumors with low coxsackie and
adenovirus receptor expression. Biomaterials. 35:5505–5516. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Shirakawa T, Sasaki R, Gardner TA, Kao C,
Zhang ZJ, Sugimura K, Matsuo M, Kamidono S and Gotoh A:
Drug-resistant human bladder-cancer cells are more sensitive to
adenovirus-mediated wild-type p53 gene therapy compared to
drug-sensitive cells. Int J Cancer. 94:282–289. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Ingemarsdotter CK, Tookman LA, Browne A,
Pirlo K, Cutts R, Chelela C, Khurrum KF, Leung EY, Dowson S, Webber
L, et al: Paclitaxel resistance increases oncolytic adenovirus
efficacy via upregulated CAR expression and dysfunctional cell
cycle control. Mol Oncol. 9:791–805. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Marchetti A, Buttitta F, Merlo G, Diella
F, Pellegrini S, Pepe S, Macchiarini P, Chella A, Angeletti CA,
Callahan R, et al: p53 alterations in non-small cell lung cancers
correlate with metastatic involvement of hilar and mediastinal
lymph nodes. Cancer Res. 53:2846–2851. 1993.PubMed/NCBI
|
|
21
|
Swisher SG, Roth JA, Nemunaitis J,
Lawrence DD, Kemp BL, Carrasco CH, Connors DG, El-Naggar AK,
Fossella F, Glisson BS, et al: Adenovirus-mediated p53 gene
transfer in advanced non-small-cell lung cancer. J Natl Cancer
Inst. 91:763–771. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Gurnani M, Lipari P, Dell J, Shi B and
Nielsen LL: Adenovirus-mediated p53 gene therapy has greater
efficacy when combined with chemotherapy against human head and
neck, ovarian, prostate, and breast cancer. Cancer Chemother
Pharmacol. 44:143–151. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Nishizaki M, Meyn RE, Levy LB, Atkinson
EN, White RA, Roth JA and Ji L: Synergistic inhibition of human
lung cancer cell growth by adenovirus-mediated wild-type p53 gene
transfer in combination with docetaxel and radiation therapeutics
in vitro and in vivo. Clin Cancer Res. 7:2887–2897. 2001.PubMed/NCBI
|
|
24
|
Swisher SG, Roth JA, Komaki R, Gu J, Lee
JJ, Hicks M, Ro JY, Hong WK, Merritt JA, Ahrar K, et al: Induction
of p53-regulated genes and tumor regression in lung cancer patients
after intratumoral delivery of adenoviral p53 (INGN 201) and
radiation therapy. Clin Cancer Res. 9:93–101. 2003.PubMed/NCBI
|
|
25
|
Hasenburg A, Fischer DC, Tong XW,
Rojas-Martinez A, Kaufman RH, Ramzy I, Kohlberger P, Orlowska-Volk
M, Aguilar-Cordova E and Kieback DG: Adenovirus-mediated thymidine
kinase gene therapy for recurrent ovarian cancer: Expression of
coxsackie-adenovirus receptor and integrins alphavbeta3 and
alphavbeta5. J Soc Gynecol Investig. 9:174–180. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Pong RC, Lai YJ, Chen H, Okegawa T,
Frenkel E, Sagalowsky A and Hsieh JT: Epigenetic regulation of
coxsackie and adenovirus receptor (CAR) gene promoter in urogenital
cancer cells. Cancer Res. 63:8680–8686. 2003.PubMed/NCBI
|
|
27
|
Kitazono M, Goldsmith ME, Aikou T, Bates S
and Fojo T: Enhanced adenovirus transgene expression in malignant
cells treated with the histone deacetylase inhibitor FR901228.
Cancer Res. 61:6328–6330. 2001.PubMed/NCBI
|
|
28
|
Watanabe T, Hioki M, Fujiwara T, Nishizaki
M, Kagawa S, Taki M, Kishimoto H, Endo Y, Urata Y, Tanaka N, et al:
Histone deacetylase inhibitor FR901228 enhances the antitumor
effect of telomerase-specific replication-selective adenoviral
agent OBP-301 in human lung cancer cells. Exp Cell Res.
312:256–265. 2006.
|
|
29
|
Bieler A, Mantwill K, Dravits T,
Bernshausen A, Glockzin G, Köhler-Vargas N, Lage H, Gansbacher B
and Holm PS: Novel three-pronged strategy to enhance cancer cell
killing in glioblastoma cell lines: Histone deacetylase inhibitor,
chemotherapy, and oncolytic adenovirus dl520. Hum Gene Ther.
17:55–70. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
El-Zawahry A, Lu P, White SJ and
Voelkel-Johnson C: In vitro efficacy of AdTRAIL gene therapy of
bladder cancer is enhanced by trichostatin A-mediated restoration
of CAR expression and downregulation of cFLIP and
Bcl-XL. Cancer Gene Ther. 13:281–289. 2006. View Article : Google Scholar
|
|
31
|
Sasaki Y, Negishi H, Idogawa M, Suzuki H,
Mita H, Toyota M, Shinomura Y, Imai K and Tokino T: Histone
deacetylase inhibitor FK228 enhances adenovirus-mediated p53 family
gene therapy in cancer models. Mol Cancer Ther. 7:779–787. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Earel JK Jr, VanOosten RL and Griffith TS:
Histone deacetylase inhibitors modulate the sensitivity of tumor
necrosis factor-related apoptosis-inducing ligand-resistant bladder
tumor cells. Cancer Res. 66:499–507. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Berghauser Pont LM, Kleijn A, Kloezeman
JJ, van den Bossche W, Kaufmann JK, de Vrij J, Leenstra S, Dirven
CM and Lamfers ML: The HDAC inhibitors scriptaid and LBH589
combined with the oncolytic virus delta24-RGD exert enhanced
anti-tumor efficacy in patient-derived glioblastoma cells. PLoS
One. 10:e01270582015. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Kim DR, Park MY, Lim HJ, Park JS, Cho YJ,
Lee SW, Yoon HI, Lee JH, Kim YS and Lee CT: Combination therapy of
conditionally replicating adenovirus and histone deacetylase
inhibitors. Int J Mol Med. 29:218–224. 2012.
|
|
35
|
MacTavish H, Diallo JS, Huang B, Stanford
M, Le Boeuf F, De Silva N, Cox J, Simmons JG, Guimond T, Falls T,
et al: Enhancement of vaccinia virus based oncolysis with histone
deacetylase inhibitors. PLoS One. 5:e144622010. View Article : Google Scholar
|
|
36
|
Vincent T, Pettersson RF, Crystal RG and
Leopold PL: Cytokine-mediated downregulation of
coxsackievirus-adenovirus receptor in endothelial cells. J Virol.
78:8047–8058. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Anders M, Christian C, McMahon M,
McCormick F and Korn WM: Inhibition of the Raf/MEK/ERK pathway
up-regulates expression of the coxsackievirus and adenovirus
receptor in cancer cells. Cancer Res. 63:2088–2095. 2003.PubMed/NCBI
|
